On September 29, 2010, Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, and Warburg Pincus, a leading global private equity firm, jointly announced that they had entered into an Investment Agreement. Under the Investment Agreement, Warburg Pincus committed to invest up to $35 million in Protox, comprised of an initial tranche of $10 million, and an additional tranche of $25 million.
Protox was advised in the negotiation of this agreement by Fasken Martineau with a team that included Iain Mant, Amanda MacAdams and Steve Saville.